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Helicobacter pylori (H. pylori) causes the most common chronic bacterial infection affecting 
over 50% of the world’s population (more than 80% in developing country). Myanmar is high 
prevalence area of H. pylori with varying in different areas. It is responsible for the cause of 
90% or more of duodenal ulcers and 60% or more of all gastric ulcer. Recently, Maastricht V 
Consensus Report recommended that concomitant therapy consisting of PPI, amoxicillin, 
clarithromycin and a nitroimidazole administered concurrently, should be the preferred first 
line non-bismuth quadruple therapy. Many researchers around the world have been being 
encouraged to work on the effectiveness of concomitant treatment nowadays. To compare the 
efficacy of concomitant and clarithromycin based triple therapy in H.pylori infected peptic 
ulcer patients. This was a hospital based randomized comparative trial conducted on the 120 
study population with H. pylori positive peptic ulcers, comprising 62 patients in the 
concomitant therapy and 58 in the triple therapy.  In the concomitant therapy group, 7 days 
regime of four drugs, clarithromycin, amoxicillin, tinidazole and rabeprazole was given and in 
the triple therapy group, 10 days regime of three drugs, clarithromycin, amoxicillin and 
rabeprazole was used. The result of the study showed that satisfactory eradication rates had 
been achieved in both groups, 93.5 % in the concomitant group comparing 87.9 % in the triple 
therapy group.  The concomitant therapy led to a non-statistically significant advantage (6%) 
over triple therapy.  Both therapies showed improvement in peptic ulcer healing with no 
statistically significant difference. The concomitant treatment regime had non-statistically 
significant superiority over triple therapy while the triple therapy can still be used as a first 
line treatment with the use of longer duration. 
Keywords: H.Pylori infection, clarithromycin based triple therapy, concomitant therapy, 
peptic ulcer, eradication rate of H.Pylori infection, peptic ulcer healing. 
INTRODUCTION 
Helicobacter pylori (H. pylori) has been co-
existing with humans for thousands of years, 
and infection with this bacterium is very 
common. It causes the most common chronic 
bacterial infection affecting over 50% of the 
world’s population (more than 80% in 
developing country)1. The prevalence of H. 
pylori in Myanmar varies in different areas 
and it was found out that in general population 
with dyspeptic symptoms the prevalence was 
48%.2 
Helicobacter pylori is a major cause 
of chronic gastritis, peptic ulcer disease, 
gastric carcinomas and gastric mucosa–
associated lymphoid tissue (MALT) 
lymphoma and has been recognized as a class 
I gastric carcinogen in 1994 by the 
International Agency for Research on Cancer 
of the World Health Organization3. It is 
responsible for the cause of 90% or more of 
duodenal ulcers and 60% or more of all 
gastric ulcer4.  
Although H. pylori is susceptible to a 
number of antimicrobials, H. pylori infection 
has proven challenging to cure because the 
prevalence of bacterial strains resistant to the 
most commonly used antimicrobials, in 
particular clarithromycin (CLA), increases. 
Most Consensus Conferences and Clinical 
guidelines recommend the prescription of a 
triple therapy including a proton pump 
inhibitor (PPI) and clarithromycin with either 
amoxicillin or metronidazole, as a first-line 
treatment.5However, the efficacy of current 
conventional clarithromycin-based triple 
therapy has decreased to an unacceptably low 
level worldwide (lower than 80%).6  In 
general, antibiotic resistance to clarithromycin 
 
 
has been identified as one of the major factors 
affecting H. pyloi eradication rate7. In 
Myanmar, a population-based endoscopic 
survey of Helicobacter pylori infection 2011 
showed that metronidazole resistance was 
37.3%, clarithromycin and amoxicillin 
resistance were 0%8.  
Therefore, researchers around the 
world have been working on the establishment 
of new eradication regime for a long time. 
Recently, Maastricht V Consensus Report 
recommended that concomitant therapy 
consisting of PPI, amoxicillin, clarithromycin 
and a nitroimidazole administered con-
currently, should be  the preferred non-
bismuth quadruple therapy as it had been 
shown to be the most effective to overcome 
antibiotic resistance. Many researchers around 
the world have been being encouraged to 
work on the effectiveness of concomitant 
treatment nowadays and so, in this research, 
the efficacy of the concomitant therapy had 
been compared with that of the standard triple 
therapy in order to provide better eradication 
treatment to Myanmar people.  
METHODS 
It is a hospital based randomized comparative 
study conducted on the 120 study population 
with H. pylori positive peptic ulcers, 
comprising 62 patients in the concomitant 
therapy and 58 in the triple therapy and had 
been carried out from December 2015 to June 
2017 at Department of Gastroenterology, 
Yangon General Hospital. Inclusion Criteria 
is proved Helicobacter pylori infected peptic 
ulcer patients who is >18 years of age. And 
Exclusion Criteria are (1) Patients who had 
previously received any treatment for 
Helicobacter pylori eradication (2) Patients 
with acute upper GI bleeding at the time of 
endoscopy. (3) Patients who had taken proton 
pump inhibitors, H2 receptor blockers, any 
antibiotic in two weeks preceding the study 
(4) Concomitant anticoagulant usage of 
enzyme inhibitor (e.g. ketoconazole) (5) 
Previous gastric surgery (6) Pregnancy or 
lactation (7) Known allergy to the prescribed 
antibiotics (8) Patients with malignant ulcer. 
They were divided randomly into two 
treatment groups according to the random 
number table. The first group (A) had 
received a 7 days concomitant regimen 
(Rabeprazole 20 mg BD, Amoxicillin 1 G 
BD, Clarithromycin 500 mg BD, and 
Tinidazole 500 mg BD) 
The second group (B) had received 
standard triple therapy for 10 days 
(Rabeprazole 20 mg BD, Amoxicillin 1G BD, 
and Clarithromycin 500 mg BD). Patients had 
been asked to return 8 weeks from the start of 
antibiotic treatment to undertake the upper GI 
endoscopy to determine the outcome of 
eradication therapy.  At that time, the stage of 
the ulcer had been noted down again and 
compared with the pretreatment condition.  
The CLO test was repeated and the 
eradication of the infection had been 
determined. 
RESULTS 
In this study, eleven patients had been lost in 
the follow up and so total 132 participants 
were recruited to meet the preset sample size 
for achieving the statistically strong 
conclusion. Most of the participants were 
above 40 years of age.  The study included 
more male proportion comprising 82 out of 
120 (68%) and only 31.7% was female. 
Regarding smoking status, 57 out of 120 
patients (47.5%) were non-smokers. Twenty-
five patients (20.8%) were current smokers, 
thirty-eight patients (31.7%) were ex-smokers.  
In this study, 73 (60.8%) of 120 
patients had never been exposed to alcohol, 
twenty-six patients (21.7%) were currently 
drinking alcohol, twenty-one patients (17.5%) 
were ex-drinkers. The most presenting clinical 
feature is both haematemesis and melaena 
which was found in 29 of 120 patients (24%), 
comprising 11 in the concomitant group and 
18 in the triple therapy group.  
In figure 1, endoscopic diagnosis, 75 
(62, 5%) of 120 patients had gastric ulcer 
alone and 38 (31.7%) had duodenal ulcer.  
Only 7 patients had both gastric and duodenal 
ulcer. In figure 2, after taking eradication 
treatment, 109 patients (90.8%) showed 
negative for H. pylori test.  Eleven patients 
still showed positive result.  In the 
concomitant group, the eradication rate was 
93.5 % and that of the triple therapy group 
was 87.9%.  The difference in eradication 
rates for the two groups was statistically not 
















 Chi-square = 0.449             p value = 0.79 



















Chi-square = 1.203            p value = 0.273 
Figure (2) Eradication rates of the two regimens 
 
As shown in figure 3, after the eradication 
treatment, ulcer healing was seen in 104 
patients (86.7%), 83.9 % in the concomitant 
group and 89.7 % in the triple therapy group.  
Unfortunately 8 patients (6.7%) were found to 
have worse ulcer, 6.5 % of the concomitant 
group and 6.9 % in the triple therapy group. 
Six patients (9.7%) of the concomitant group 
had ulcers in the static stage comparing with 2 
patients (3.4%) of the triple therapy group. 
Most of the patients did not experience any 
adverse effects from their respective 
treatment.  However, 38 out of 120 patients 
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Chi-square = 1.869           p value = 0.393 
Figure (3) Ulcer Progress after eradication treatment 
 
DISCUSSION 
Most of the socio-demographic characteristics 
(age, sex, occupation, smoking and alcohol 
drinking) were similar in both groups and 
there was no statistically significant 
difference. In contrary to currently accepted 
pathology, endoscopic diagnosis in this study 
showed that gastric ulcer was nearly twice in 
common than duodenal ulcer.  Seventy five 
(62.5%) of 120 patients had gastric ulcer 
alone and 38 (31.7%) had duodenal ulcer 
only.  But 7 patients had both gastric and 
duodenal ulcer.  However, there was not 
statistically significant in the comparing 
groups concerning the occurrence of GU and 
DU.   
In this study, eradication rate of the 10 
days triple therapy group was 87.9%.  This 
finding was quite higher than that in findings 
of some recent studies and consensus reports 
from developed countries.  The Toronto 
Consensus, a meta-analysis of 12 studies, 
found that the efficacy of clarithromycin -
based triple therapy was decreased from 80% 
in studies from 2000 to 2005 to only 62% in 
more recent studies (2006-2011)9. However, it 
was consistent with the result in a recent 
Myanmar study, in which the eradication rate 
of 10 day triple therapy in dyspeptic patients 
was found to be 95%10. Moreover, Maastricht 
V Consensus reported that rabeprazole and 
esomeprazole were less effected by CYP2C19 
genotype. In this study, rabeprazole 20 mg 
twice a day had been used as PPI in 
eradication regieme, which might lead to a 
higher eradication rate than other developed 
countries.  In addition, one of the key factors 
to influence the eradication rate was duration 
of regime.  One review article concluded that 
increasing the duration of PPI-based triple 
therapy raised the H. pylori eradication rate.   
Prolonging treatment duration, from 7 
to 10 days or from 10 to 14 days, was 
associated with a significantly higher 
eradication rate11. In this study, 10 days triple 
therapy was resulted in 87.9 % eradication 
rate.  Therefore, the eradication rate might be 
more than 87.9% if duration would be 
extended to 14 days as recommended.  
The eradication rate of 7 days con-
comitant therapy, twice a day, was 93.5%. 
The efficacy of concomitant therapy was 
highly depended on clarithromycin and 
metronidazole resistance. In Myanmar, a 
population-based endoscopic survey of 
Helicobacter pylori infection 2011 showed 
that metronidazole resistance was 37.3%.8. 
There had been irrational use of 
metronidazole which could be available as an 





















 But, unlike clarithromycin, metro-
nidazole resistance can be overcome to some 
extent by increasing dose, frequency, and 
duration of the prescription. 
In this study, the eradication rates of 
two groups were 93.5% for the concomitant 
group and 87.9% for the triple therapy group 
respectively.  Although 7 days concomitant 
group yielded a higher eradication rate than 
10 days triple therapy group, the difference 
was not significant statistically.  The study 
had clearly showed that the 10 days triple 
therapy regime was still effective in 
eradication treatment.  The reason might be 
due to the fact that the resistance to the main 
drug, clarithromycin, was still low in 
Myanmar12. In this study, improvement of 
ulcer was seen in 86.7% of cases, but there 
was no statistically significant between 
concomitant and triple therapy groups (p 
value=0.393). 
CONCLUSION 
This was a hospital based randomized 
comparative trial conducted on the 120 study 
population with H. pylori positive peptic 
ulcers, comprising 62 patients in the 
concomitant therapy and 58 in the triple 
therapy.  In the concomitant therapy group, 7 
days regime of four drugs, clarithromycin, 
amoxicillin, tinidazole and rabeprazole was 
given and in the triple therapy group, 10 days 
regime of three drugs, clarithromycin, 
amoxicillin and rabeprazole was used.  The 
baseline characteristics of the participants 
were not much different.  
The drug compliance was seen to be 
satisfactory in both regimes with little 
untoward effects. The result of the study 
showed that satisfactory eradication rates had 
been achieved in both groups, 93.5 % in the 
concomitant group comparing 87.9 % in the 
triple therapy group.  The concomitant 
therapy led to a non-statistically significant 
advantage (6%) over triple therapy.  Both 
therapies showed improvement in peptic ulcer 
healing with no statistically significant 
difference. 
According to the results obtained in 
this study, it could be concluded that the 
concomitant treatment regime had non-
statistically significant superiority over triple 
therapy while the triple therapy can still be 
used as a first line treatment with the use of 
longer duration. 
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